 Premal Trivedi
Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Portasystemic Shunt, Transjugular Intrahepatic | 7 | 2025 | 38 | 3.580 |
Why?
| | Vena Cava Filters | 8 | 2025 | 64 | 2.930 |
Why?
| | Esophageal and Gastric Varices | 4 | 2021 | 35 | 2.570 |
Why?
| | Radiology, Interventional | 4 | 2024 | 32 | 2.530 |
Why?
| | Hepatorenal Syndrome | 3 | 2025 | 15 | 2.480 |
Why?
| | Ischemic Attack, Transient | 3 | 2022 | 67 | 2.000 |
Why?
| | Renal Replacement Therapy | 2 | 2025 | 93 | 1.780 |
Why?
| | Radiography, Interventional | 2 | 2025 | 122 | 1.730 |
Why?
| | Liver Transplantation | 3 | 2025 | 766 | 1.610 |
Why?
| | Radiology | 3 | 2023 | 170 | 1.450 |
Why?
| | Medicare | 8 | 2025 | 799 | 1.430 |
Why?
| | Cholestasis | 2 | 2023 | 207 | 1.210 |
Why?
| | Device Removal | 3 | 2025 | 140 | 1.190 |
Why?
| | Practice Patterns, Physicians' | 6 | 2021 | 1336 | 1.180 |
Why?
| | Hyperaldosteronism | 2 | 2025 | 12 | 1.050 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2021 | 134 | 0.970 |
Why?
| | Pulmonary Embolism | 4 | 2021 | 239 | 0.920 |
Why?
| | Renal Dialysis | 2 | 2020 | 457 | 0.900 |
Why?
| | United States | 23 | 2025 | 15220 | 0.870 |
Why?
| | Peripheral Arterial Disease | 2 | 2022 | 490 | 0.860 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2022 | 232 | 0.790 |
Why?
| | Stroke | 2 | 2022 | 1154 | 0.790 |
Why?
| | Treatment Outcome | 15 | 2026 | 11120 | 0.760 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2026 | 353 | 0.710 |
Why?
| | Angioplasty, Balloon | 1 | 2022 | 93 | 0.700 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2021 | 27 | 0.670 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2021 | 88 | 0.640 |
Why?
| | End Stage Liver Disease | 1 | 2021 | 76 | 0.640 |
Why?
| | Specialization | 1 | 2020 | 130 | 0.600 |
Why?
| | Liver Neoplasms | 2 | 2026 | 740 | 0.590 |
Why?
| | Medicine | 1 | 2020 | 125 | 0.580 |
Why?
| | Retrospective Studies | 15 | 2025 | 16273 | 0.560 |
Why?
| | Neuroimaging | 1 | 2020 | 272 | 0.560 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2018 | 19 | 0.550 |
Why?
| | Graft Occlusion, Vascular | 1 | 2018 | 39 | 0.540 |
Why?
| | Humans | 40 | 2026 | 141187 | 0.520 |
Why?
| | Leptin | 2 | 2008 | 242 | 0.510 |
Why?
| | Ascites | 1 | 2016 | 47 | 0.480 |
Why?
| | Healthcare Disparities | 1 | 2022 | 666 | 0.480 |
Why?
| | Lower Extremity | 1 | 2020 | 439 | 0.470 |
Why?
| | Hypertension, Portal | 1 | 2016 | 64 | 0.470 |
Why?
| | Endovascular Procedures | 1 | 2020 | 355 | 0.460 |
Why?
| | Logistic Models | 5 | 2021 | 2086 | 0.450 |
Why?
| | Emergency Service, Hospital | 3 | 2022 | 2172 | 0.450 |
Why?
| | Adrenal Glands | 2 | 2025 | 80 | 0.430 |
Why?
| | Aged, 80 and over | 9 | 2026 | 7856 | 0.430 |
Why?
| | Aged | 14 | 2026 | 24574 | 0.380 |
Why?
| | Databases, Factual | 6 | 2022 | 1444 | 0.380 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1597 | 0.370 |
Why?
| | Radiography | 3 | 2023 | 844 | 0.360 |
Why?
| | Catheterization | 2 | 2023 | 182 | 0.340 |
Why?
| | Constriction, Pathologic | 2 | 2023 | 238 | 0.340 |
Why?
| | Patient Discharge | 3 | 2022 | 932 | 0.330 |
Why?
| | Hemodynamics | 2 | 2025 | 1100 | 0.330 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 2070 | 0.320 |
Why?
| | Apoptosis | 2 | 2008 | 2574 | 0.300 |
Why?
| | Male | 18 | 2026 | 69783 | 0.290 |
Why?
| | Muscle Cells | 1 | 2007 | 42 | 0.270 |
Why?
| | Neoplasms | 1 | 2023 | 2741 | 0.270 |
Why?
| | Middle Aged | 12 | 2026 | 34434 | 0.270 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5636 | 0.260 |
Why?
| | Risk Factors | 5 | 2025 | 10438 | 0.260 |
Why?
| | Cardiomegaly | 1 | 2007 | 172 | 0.250 |
Why?
| | Female | 17 | 2026 | 75515 | 0.250 |
Why?
| | Cosyntropin | 1 | 2025 | 7 | 0.240 |
Why?
| | Yttrium Radioisotopes | 1 | 2026 | 63 | 0.240 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 368 | 0.240 |
Why?
| | Goldenhar Syndrome | 1 | 2025 | 11 | 0.240 |
Why?
| | Cranial Fossa, Middle | 1 | 2025 | 16 | 0.240 |
Why?
| | Fistula | 1 | 2025 | 47 | 0.230 |
Why?
| | Hospitals | 2 | 2021 | 696 | 0.220 |
Why?
| | Intracranial Hypotension | 1 | 2025 | 58 | 0.220 |
Why?
| | Myocytes, Cardiac | 1 | 2008 | 535 | 0.210 |
Why?
| | Biomarkers | 2 | 2025 | 4174 | 0.210 |
Why?
| | Cohort Studies | 4 | 2023 | 5799 | 0.210 |
Why?
| | Aldosterone | 1 | 2023 | 43 | 0.200 |
Why?
| | Embolization, Therapeutic | 1 | 2026 | 241 | 0.200 |
Why?
| | Adult | 10 | 2025 | 39177 | 0.200 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2892 | 0.200 |
Why?
| | Gallbladder Diseases | 1 | 2022 | 12 | 0.190 |
Why?
| | Watchful Waiting | 1 | 2023 | 84 | 0.190 |
Why?
| | Atherectomy | 1 | 2022 | 37 | 0.190 |
Why?
| | Forecasting | 1 | 2024 | 384 | 0.190 |
Why?
| | Hospitalization | 3 | 2021 | 2255 | 0.180 |
Why?
| | Cholecystostomy | 1 | 2021 | 3 | 0.180 |
Why?
| | Cholecystitis, Acute | 1 | 2021 | 23 | 0.170 |
Why?
| | Femoral Artery | 1 | 2022 | 184 | 0.170 |
Why?
| | Cholecystectomy | 1 | 2021 | 58 | 0.170 |
Why?
| | Vena Cava, Inferior | 1 | 2021 | 74 | 0.170 |
Why?
| | Oropharynx | 1 | 2020 | 45 | 0.170 |
Why?
| | Mouth | 1 | 2020 | 88 | 0.160 |
Why?
| | Larynx | 1 | 2020 | 63 | 0.160 |
Why?
| | Administrative Claims, Healthcare | 1 | 2020 | 26 | 0.160 |
Why?
| | Cardiologists | 1 | 2020 | 45 | 0.160 |
Why?
| | Radiologists | 1 | 2020 | 52 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 222 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2020 | 74 | 0.150 |
Why?
| | Time Factors | 3 | 2020 | 6956 | 0.150 |
Why?
| | Odds Ratio | 1 | 2021 | 1052 | 0.140 |
Why?
| | Recurrence | 1 | 2021 | 1110 | 0.140 |
Why?
| | Acute Disease | 1 | 2021 | 1008 | 0.140 |
Why?
| | Hemorrhage | 1 | 2023 | 760 | 0.140 |
Why?
| | Inpatients | 2 | 2019 | 507 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 618 | 0.140 |
Why?
| | Socioeconomic Factors | 1 | 2022 | 1306 | 0.140 |
Why?
| | Vascular Patency | 1 | 2018 | 109 | 0.140 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 282 | 0.130 |
Why?
| | Radiology Department, Hospital | 1 | 2017 | 16 | 0.130 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2017 | 68 | 0.130 |
Why?
| | Linear Models | 2 | 2017 | 857 | 0.130 |
Why?
| | Prosthesis Implantation | 1 | 2018 | 157 | 0.130 |
Why?
| | Adolescent | 6 | 2021 | 22007 | 0.130 |
Why?
| | Venous Thromboembolism | 2 | 2018 | 337 | 0.130 |
Why?
| | Drug Utilization | 1 | 2017 | 169 | 0.130 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 2087 | 0.130 |
Why?
| | Inservice Training | 1 | 2017 | 122 | 0.120 |
Why?
| | Personnel Selection | 1 | 2017 | 86 | 0.120 |
Why?
| | Ambulatory Care | 1 | 2020 | 582 | 0.120 |
Why?
| | Obesity | 1 | 2008 | 3004 | 0.120 |
Why?
| | Surgeons | 1 | 2020 | 335 | 0.110 |
Why?
| | Hospital Mortality | 2 | 2018 | 924 | 0.110 |
Why?
| | Comorbidity | 2 | 2018 | 1662 | 0.110 |
Why?
| | Prevalence | 1 | 2021 | 2772 | 0.110 |
Why?
| | Faculty, Medical | 1 | 2017 | 295 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1123 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2902 | 0.100 |
Why?
| | Anticoagulants | 1 | 2017 | 675 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1490 | 0.090 |
Why?
| | Sex Factors | 1 | 2018 | 2058 | 0.090 |
Why?
| | Young Adult | 4 | 2021 | 13673 | 0.090 |
Why?
| | Internship and Residency | 1 | 2022 | 1235 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5200 | 0.080 |
Why?
| | Heart Failure | 2 | 2018 | 2088 | 0.080 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2022 | 147 | 0.080 |
Why?
| | Length of Stay | 1 | 2016 | 1254 | 0.080 |
Why?
| | Positron-Emission Tomography | 2 | 2022 | 310 | 0.080 |
Why?
| | Survival Rate | 2 | 2018 | 1970 | 0.080 |
Why?
| | Rats, Zucker | 1 | 2008 | 33 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2560 | 0.070 |
Why?
| | Mice, Obese | 1 | 2007 | 67 | 0.070 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2007 | 97 | 0.070 |
Why?
| | Caspase 3 | 1 | 2007 | 250 | 0.060 |
Why?
| | Catalysis | 1 | 2007 | 320 | 0.060 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2026 | 14 | 0.060 |
Why?
| | Intracranial Pressure | 1 | 2006 | 60 | 0.060 |
Why?
| | Adrenalectomy | 1 | 2025 | 69 | 0.060 |
Why?
| | Microspheres | 1 | 2026 | 142 | 0.060 |
Why?
| | Veins | 1 | 2025 | 70 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1073 | 0.060 |
Why?
| | Cholangiocarcinoma | 1 | 2026 | 94 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2025 | 417 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1973 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 1 | 2008 | 2520 | 0.050 |
Why?
| | Myocardium | 1 | 2007 | 928 | 0.050 |
Why?
| | Interdisciplinary Research | 1 | 2022 | 26 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 109 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2022 | 188 | 0.040 |
Why?
| | Gallbladder | 1 | 2021 | 15 | 0.040 |
Why?
| | Brain Injuries | 1 | 2006 | 502 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 2020 | 34 | 0.040 |
Why?
| | Insulin Resistance | 1 | 2008 | 1225 | 0.040 |
Why?
| | Rats | 1 | 2008 | 5629 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 704 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2020 | 715 | 0.040 |
Why?
| | Hospital Bed Capacity | 1 | 2018 | 27 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2008 | 4404 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2018 | 115 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 137 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 212 | 0.030 |
Why?
| | Animals | 2 | 2008 | 37657 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 339 | 0.030 |
Why?
| | Signal Transduction | 1 | 2008 | 5144 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2025 | 2746 | 0.030 |
Why?
| | Career Choice | 1 | 2017 | 232 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1243 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 531 | 0.030 |
Why?
| | Age Factors | 1 | 2018 | 3292 | 0.020 |
Why?
| | Mice | 1 | 2007 | 18048 | 0.020 |
Why?
| | Curriculum | 1 | 2017 | 1033 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2999 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7739 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5929 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 111 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2006 | 203 | 0.010 |
Why?
| | Observer Variation | 1 | 2006 | 355 | 0.010 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2006 | 270 | 0.010 |
Why?
| | Child | 2 | 2017 | 22308 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11457 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2006 | 3348 | 0.010 |
Why?
|
|
Trivedi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|